CINECA IRIS Institutional Research Information System

CIABATTI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.060
EU - Europa 1.722
AS - Asia 1.194
SA - Sud America 219
AF - Africa 85
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 6.286
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.966
IT - Italia 583
CN - Cina 419
SE - Svezia 373
SG - Singapore 329
DE - Germania 219
HK - Hong Kong 212
BR - Brasile 198
GB - Regno Unito 161
BG - Bulgaria 135
CA - Canada 78
VN - Vietnam 69
FI - Finlandia 63
TR - Turchia 62
RU - Federazione Russa 58
CI - Costa d'Avorio 46
FR - Francia 36
IN - India 33
BE - Belgio 24
UA - Ucraina 24
JP - Giappone 18
SN - Senegal 14
NL - Olanda 8
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
ES - Italia 7
NG - Nigeria 7
SA - Arabia Saudita 6
VE - Venezuela 6
BD - Bangladesh 5
EC - Ecuador 5
GR - Grecia 4
KE - Kenya 4
KR - Corea 4
LT - Lituania 4
MX - Messico 4
PK - Pakistan 4
PL - Polonia 4
AT - Austria 3
CH - Svizzera 3
CO - Colombia 3
EG - Egitto 3
IQ - Iraq 3
PH - Filippine 3
TW - Taiwan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
AU - Australia 2
BS - Bahamas 2
EU - Europa 2
HR - Croazia 2
ID - Indonesia 2
IE - Irlanda 2
IL - Israele 2
IR - Iran 2
KZ - Kazakistan 2
MA - Marocco 2
PR - Porto Rico 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BB - Barbados 1
BJ - Benin 1
BM - Bermuda 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
LY - Libia 1
MD - Moldavia 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
PY - Paraguay 1
SR - Suriname 1
TG - Togo 1
Totale 6.286
Salva come PNG Salva come JPEG
Città #
Ashburn 330
Serra 274
Fairfield 272
Woodbridge 270
Santa Clara 260
Chandler 237
Hong Kong 207
Houston 206
Ann Arbor 205
Singapore 144
Sofia 131
Seattle 128
Beijing 120
Shanghai 117
Wilmington 101
New York 89
Cambridge 85
Boardman 78
Princeton 70
Ottawa 67
Milan 57
Munich 53
Medford 47
Abidjan 46
Lawrence 44
London 42
Florence 39
Des Moines 37
Lancaster 29
Bremen 27
Dearborn 27
Izmir 26
Pisa 26
Los Angeles 25
Nanjing 23
Brussels 22
Istanbul 22
San Diego 21
Jacksonville 18
Rome 17
Dong Ket 15
Dakar 14
São Paulo 14
Turku 14
Frankfurt am Main 13
Helsinki 13
Shenyang 13
Nanchang 12
Fuzhou 11
Alessandria 10
Düsseldorf 10
Hebei 9
Nuremberg 9
Redwood City 9
Campinas 8
Council Bluffs 8
Duncan 8
Kunming 8
Monza 8
Phoenix 8
Rio de Janeiro 8
Tashkent 8
Tokyo 8
Hefei 7
Lagos 7
Toronto 7
Washington 7
Boston 6
Chicago 6
Columbus 6
Kocaeli 6
Ogden 6
The Dalles 6
Changsha 5
Dallas 5
Falkenstein 5
Hangzhou 5
Jiaxing 5
Palermo 5
Pune 5
Westminster 5
Boulder 4
Detroit 4
Fortaleza 4
Guangzhou 4
Livorno 4
Nairobi 4
Olomouc 4
Piracicaba 4
Quanzhou 4
Riyadh 4
Turin 4
Belo Horizonte 3
Bern 3
Brooklyn 3
Curitiba 3
Franca 3
Guarulhos 3
Guayaquil 3
Ho Chi Minh City 3
Totale 4.449
Salva come PNG Salva come JPEG
Nome #
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 216
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study 199
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 185
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 176
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 175
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 166
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 164
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 163
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 154
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 152
MDS: An Integrated Workup for a Correct Diagnosis 151
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 151
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 149
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 148
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 148
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 147
Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia 143
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 143
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 140
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 140
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 137
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 131
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 130
Combined FAMD and ANOVA investigation leads to significant association between the hOCT1/ABCB1 diplotype and both efficacy and tolerability in patients affected by chronic myeloid leukemia 130
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes 129
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation 121
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line 118
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 118
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) 118
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 117
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 111
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 109
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 109
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 107
Cell clonality in hypereosinophilic syndrome: what pathogenetic role? 104
Conventional Cytogenetics, ACGH, and PCR as Integrated Workup for a Correct Diagnosis of MDS 104
R-IPSS, RPS14 AND WT1 LEVELS ARE THE BEST PROGNOSTIC FACTORS FOR PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES DURING AZACITIDINE TREATMENT. 102
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 101
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation 95
THE C.480C>G POLYMORPHISM OF HOCT1 TRANSPORTER INFLUENCES IMATINIB CLEARANCE IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 89
TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA 89
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 88
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study 83
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 83
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 81
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.sinensis leaf extract. 80
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 76
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: Correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 72
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms 68
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 67
Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells 66
null 51
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network 51
Totale 6.445
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.120
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021368 27 17 22 15 26 22 21 26 43 31 39 79
2021/2022670 15 32 12 39 111 92 24 17 70 28 53 177
2022/2023863 133 164 53 72 71 94 8 67 124 15 57 5
2023/2024494 55 39 66 31 52 86 28 12 6 19 24 76
2024/20251.731 6 60 11 99 198 202 174 114 145 218 178 326
2025/202688 88 0 0 0 0 0 0 0 0 0 0 0
Totale 6.445